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Background: The characteristics of circulating inflammatory cells (leukocytes) in patients 
undergoing heart surgery remains poorly understood. Recently, neutrophil-to-lymphocyte  
ratio (NLR) and specific monocyte subsets (based on CD14/CD16 expression) have 
been suggested as markers of inflammation and predictors of outcomes. The present 
study aims to characterize the influence cardiac surgery with cardiopulmonary bypass 
has on specific circulating leukocytes.
Methods: All enrolled patients had blood samples taken pre- (0  days), early post- 
(5 days), and late post- (90 days) surgery. Complete blood counts were performed and 
whole leukocyte isolations were obtained from blood samples and analyzed with flow 
cytometry. Fluorophore-linked antibodies (CD45, CD11b, CD14, and CD16) were added 
to the blood cell isolations and later assessed by flow cytometry.
results: Seventeen patients were enrolled and samples obtained at 0, 5, and 90 days. 
We demonstrated a significant increase in NLR (2.2-fold; p = 0.0028) and CD16 mean 
fluorescence index (MFI-measure fluorescence intensity shift of CD16 in a gated cell 
population) early at day 5 (2.0-fold; p = 0.0051). Both NLR and CD16 MFI levels generally 
returned to normal by day 90. There was a significant positive correlation between NLR 
and CD16 MFI (r2 = 0.29; p = 0.0064). Adverse cardiovascular event (AE) was defined 
as prolonged length of hospitalization or readmission to hospital for cardiac reasons 
after discharge was seen in 59% of patients (no deaths occurred). In an unadjusted 
Abbreviations: AE, adverse cardiovascular event; CABG, coronary artery bypass grafting; CPB, cardiopulmonary bypass; 
CIHR, Canadian Institute of Health Research; COPD, chronic obstructive pulmonary disease; Cr, serum creatinine; CRP, 
C-reactive protein; CVICU, Cardiovascular Intensive Care Unit; EF, ejection fraction; FSC, forward scatter; HF, heart failure; 
IL-1β, interleukin one beta; LA, left atrium; MFI, mean fluorescence index; NLR, neutrophil-to-lymphocyte ratio; NSTEMI, 
non-ST elevation myocardial infarction; NYHA, New York Heart Association; PLR, platelet-to-lymphocyte ratio; QEII HSC, 
Queen Elizabeth II Health Sciences Centre; REACH, Restitution Enhancement in Arthritis and Chronic Heart disease; SSC, 
side scatter; STEMI, ST elevation myocardial infarction; TNFα, tumor necrosis factor alpha.
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inTrODUcTiOn
The role of inflammation and its effector cells (circulating leu-
kocytes) in patients undergoing heart surgery remains poorly 
understood. Traditionally, it has been difficult to differentiate 
between the normal beneficial inflammatory response needed for 
healing and components of the inflammatory response that can 
be linked to disease progression. There is increasing evidence that 
changes in circulating leukocytes associated with disease hold 
important prognostic information that could be used clinically 
(1–5). In particular, cardiopulmonary bypass (CPB), which is 
used extensively in patients undergoing heart surgery, has often 
been suggested as an important inflammatory stimulus respon-
sible for significant changes in leukocytes that remain poorly 
defined (6–8).
Neutrophil-to-lymphocyte ratio (NLR) obtained from patients 
prior to surgery has been reported to be an independent predic-
tor for the development of adverse events in patients undergoing 
cardiac surgery (1, 2, 5). This is also true for patients with acute 
coronary events and not specific to heart surgery, suggesting that 
NLR may represent a measure of the burden of inflammation in 
patients (9). The mechanism by which NLR is linked to patient 
outcome remains unclear. However, some investigators have 
suggested that major stress, such as surgery, results in significant 
changes in neuroendocrine factors such as cortisol, which could 
be responsible for the associated lymphopenia and affect NLR 
(10).
Similarly, the relative proportion of specific monocyte subsets 
has been linked to adverse outcomes in patients suffering from 
cardiovascular disease (3, 4, 11, 12). Monocyte subsets character-
ized by their variable expression of lipopolysaccharide receptor 
CD14 and Fcγ-III receptor CD16 in peripheral blood have been 
traditionally divided into classical (CD14++CD16−, M1), inter-
mediate (CD14++CD16+), and non-classical (CD14+CD16+, 
M2) monocytes (13, 14). Several studies have suggested that 
increased expression of CD16 either with a greater proportion in 
intermediate or non-classical monocytes can be used to predict 
adverse events in patients with heart disease (3, 13). Moreover, in 
a large study of 951 patients undergoing elective coronary angi-
ography, Rogacev and colleagues were able to demonstrate how 
elevated values of intermediate monocytes could independently 
be used to predict long-term adverse cardiovascular outcomes in 
these patients (4). Similar evidence linking non-classical mono-
cytes to chronic heart failure (HF), particularly HF with normal 
ejection fraction (EF) have been reported (11, 12, 15). While 
much of the evidence would suggest that increased CD16 expres-
sion is associated with worse outcomes, there remains significant 
knowledge gaps particularly in patients during heart surgery.
In the present study, we sought to examine and characterize 
circulating leukocytes in a group of patients undergoing heart 
surgery for the treatment of ischemic heart disease. More specifi-
cally, we hypothesized that circulating leukocytes counts (NLR) 
and/or more detailed expression of surface markers (CD14 and 
CD16 expression) can help clinicians in better understanding 
the burden of inflammation and correlate findings with clinical 
outcomes.
MaTerials anD MeThODs
study Population and Objectives
Patients were enrolled prospectively based on admission to 
the QEII Health Science Centre (Halifax) with ischemic heart 
disease requiring surgical revascularization or coronary artery 
bypass grafting (CABG). Informed consent was obtained for all 
participating patients and all patients received standard care in 
terms of treatment. Patient enrollment was determined based 
on participating surgeon and availability of the laboratory team 
to perform immediate processing of blood and tissue sampling. 
This also meant that the majority of patients had a history of 
prior acute coronary syndrome (ACS) and were recovering 
from their myocardial injury at the time of study. The exclu-
sion criteria included the need for emergent surgery, severe left 
ventricular dysfunction, and planned concomitant surgery. The 
present investigation represents findings from a sub-study of a 
research program called Restitution Enhancement in Arthritis 
and Chronic Heart disease (REACH), in which the objective was 
to study mechanisms that would favor resolution of myocardial 
inflammation in patients with ischemic injury and heart disease. 
The objectives of the present investigation were to characterize 
circulating leukocyte and monocyte populations based on CD14 
analysis of AE, we identified NLR as a likely predictor of AE, which meant that patients 
developing AE had a significantly higher baseline NLR (p = 0.0065), something that was 
not observed with CD16 MFI (p = 0.2541).
conclusion: Cardiac surgery is associated with a significant increase in NLR and CD16 
MFI (non-classical monocytes) early after surgery corresponding to the early inflamma-
tory phase after surgery. Furthermore, we have, for the first time, identified a significant 
correlation between NLR and CD16 MFI. While the mechanism for this relationship 
remains unclear, our findings support the use of a simple test of NLR as a biomarker of 
inflammation for predicting outcomes in cardiac surgery patients.
Keywords: reach project, biomarkers of inflammation, cD16 expression, intermediate monocytes, phenotypic 
shift, nlr, cardiac surgery, non-classical monocytes
TaBle 1 | Patient characteristics.
Parameters Patients (n = 17)
Age 65.9 (44–84)
Female gender 4/17
Diabetes 3/17
Ejection fraction (EF) 60.1 (40–86)
EF > 50% 14/17
Atrial fibrillation 1/17
BMI 28.4 (20–33.3)
Normal 4/17
Pre-obese 7/17
Obese 6/17
Urgency In-hospital 14/17
Elective 3/17
Procedure type Coronary artery bypass grafting 
(CABG)
16/17
CABG + aortic valve 1/17
Clinical frailty CFS class 4/5 7/17
Echocardiogram LV diast diameter 4.7 (4–5.5)
LV syst diameter 2.8 (2.2–3.4)
Left atrium diameter 4 (2.8–4.9)
E/A ratio 1.2 (0.5–2)
TaBle 2 | leukocyte counts.
Day 0 Day 5 p
WBC (×109 cells/L) 6.9 + 0.5 8.4 + 0.6 0.08
Neutrophil (×109 cells/L) 4.3 + 0.3 5.7 + 0.5 0.04*
Lymphocyte (×109 cells/L) 1.9 + 0.2 1.5 + 0.2 0.06
Monocyte (×109 cells/L) 0.6 + 0.05 0.9 + 0.08 0.0074*
Platelet (×109 cells/L) 235.8 + 15.0 228.0 + 23.7 0.78
For statistical analysis, t-test was used; *P < 0.05.
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and CD16 expression in patients enrolled in the REACH study. 
Blood samples were drawn on the day of surgery (day 0), prior 
to discharge from hospital (day 5), and at the follow-up appoint-
ment (day 90). Samples were all processed immediately for flow 
cytometry and processed for future analysis using standard bio-
banking approaches.
study Procedures
Intraoperative Management
In all patients, cardiac surgery was performed with CPB and 
anticoagulation was achieved using intravenous heparin given at 
a dose of 400 IU/kg with a target activated clotting time greater 
than 450 s. Antifibrinolytic agents were given to all patients and 
consisted mainly of tranexamic acid. Intermittent cold blood 
cardioplegia was delivered in an antegrade or retrograde fashion 
based on surgeon preference. Protamine sulfate was given for 
reversal of heparin in all patients.
Patients also received routine baseline 12-lead electrocardio-
grams upon admission to the cardiovascular intensive care unit. 
Resumption of routine postoperative medications occurred as 
indicated and included anti-platelet agents within 24 h, statins, 
and β-blockers.
Variable Selection
Preoperative clinical characteristics of interest included age, 
gender, New York Heart Association (NYHA) functional class, 
urgency of surgery (urgent if required within 24 h, in-hospital 
urgent if the patient required hospitalization until the time of 
surgery, and elective or outpatient), and diabetes. Intraoperative 
variables included pump time and clamp time. Blood samples 
were obtained pre-surgery, 5–7 days post-surgery, and >42 days 
post-surgery. Standard blood analysis, including complete 
blood counts, NLR, platelet-to-lymphocyte ratio, peak troponin 
(collected within 24  h of surgery), and monocyte counts were 
obtained.
Blood Processing and Flow Cytometry
In brief, heparinized blood samples (100  μL) were incubated 
with anti-human antibodies linked to different fluorescent labels, 
CD45-PerCp-Cy5.5 (BioLegend, San Diego, CA, USA), CD11b-
FITC (BioLegend, San Diego, CA, USA), CD14-PE (eBioscience, 
San Diego, CA, USA), and CD16-APC (eBioscience, San Diego, 
CA, USA). Labeled whole blood samples were then incubated 
with 1× FACS Lysing Solution (BD Biosciences, San Jose, CA, 
USA) in order to lyse red blood cells. Samples were then fixed 
with 1% paraformaldehyde solution prepared in PBS with 0.1% 
sodium azide. Isotype controls were used for negative gating to 
identify the level of non-specific binding. Data were acquired 
using the FACS Calibur (BD Biosciences, San Jose, CA, USA) 
then analyzed using FlowJo (FlowJo LLC, Ashland, OR, USA). 
Monocyte gating was performed by gating on cells with the use of 
forward and side scatter (FSC and SSC), which was then applied 
to a CD45 ×  SSC dot plot. The CD45+ events were gated and 
applied to a CD11b ×  SSC dot plot. The CD11b+ events were 
gated and applied on a CD16 × CD14 dot plot for characteriza-
tion of distinct monocyte subsets and CD16 mean fluorescence 
index (MFI).
clinical Data Definitions and Outcomes
Clinical data collection and outcomes were recorded using 
standard case report forms. Follow-up was chosen based on 
predicted clinical course of patients after myocardial injury that 
underwent CABG surgery. This means an initial myocardial 
injury characterized at the time of enrollment followed by clinical 
improvement and resolution (6 weeks to 3 months). Biological 
samples were used to study cellular markers of inflammation. The 
clinical outcomes of interest focused on adverse cardiovascular 
events (AE). We chose a composite outcome, which included 
prolonged hospitalization (length of stay >9 days), readmission 
to hospital after discharge for cardiac reason, persistent HF at 
follow-up NYHA class III or IV, and inability to wean diuretics 
for symptoms of congestion (dyspnea, peripheral edema).
Data analysis
All data analysis was performed using GraphPad Prism 6 
(GraphPad Software Inc., La Jolla, CA, USA). Categorical 
variables were reported as frequencies and percentages and were 
analyzed by chi-square.
ethics
This study was conducted with the full approval of the institu-
tional (Nova Scotia Health Authority) Research Ethics Board. All 
personal identifiers were stripped prior to data analysis to ensure 
patient anonymity and confidentiality.
FigUre 2 | Whole blood leukocytes isolated from patients’ blood samples were stained with cD11b, cD45, cD14, and cD16 and frequencies of 
monocyte subsets were measured by flow cytometry. (a) Representative images of flow cytometry gating strategy used to identify monocyte phenotypes from 
whole leukocyte blood samples. (B) Represents subpopulation percentage findings from 13 patients in terms of M1, intermediate, and M2 at day 0 or just prior to 
surgery.
FigUre 1 | neutrophil-to-lymphocyte ratio (nlr) and monocyte change 5 days post-surgery. (a) T-test was performed to compare NLR between day 0 
and day 5 samples (p = 0.0028). (B) Monocyte counts per microliter in day 0 and day 5 samples (p = 0.0074). For statistical analysis, two-tailed unpaired t-test was 
used; *P < 0.05, **P < 0.01, and ***P < 0.001.
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resUlTs
Patient characteristics
During the study period, a total of 25 patients were screened 
and approached for consent with 17 patients consenting; yield-
ing a 68% enrollment rate as our study population (Table  1). 
The majority of patients were males (76.5%), with normal EF 
(70.6%), requiring surgery while in hospital after a recent 
myocardial infarction (non-ST elevation myocardial infarction 
82.4%), undergoing surgical coronary revascularization or 
CABG surgery (100%). All patients received the same standard 
of care.
FigUre 4 | cD16 and cD14 mean fluorescence index (MFi) values in various time points. (a) Graph showing CD16 MFI differences between the various 
blood collection time points. There was an increase in CD16 MFI on day 5 when compared to baseline (p = 0.0051). (B) CD14 MFI was not significantly different 
between day 0, day 5, and day 90. Day 0 (n = 13), day 5 (n = 11), and day 90 (n = 7) samples. For statistical analysis, two-tailed unpaired t-test was used; 
*P < 0.05, **P < 0.01, and ***P < 0.001.
FigUre 3 | Monocyte subsets changes over time in circulating blood. (a) The flow cytometry dot plots of an individual patient at day 0 (n = 13), day 5 
(n = 11), and day 90 (n = 9) post-surgical intervention. (B) Graph demonstrating the change in the M1 monocyte subpopulation over time showing a decrease at 
day 5 from baseline (p = 0.0301). (c) Intermediate subpopulation showed a mean 1.47-fold increase at day 5 from baseline (p = 0.0025). (D) M2 subpopulation 
was observed to have a 1.69-fold increase at day 5 from baseline (p = 0.0257). Day 90 samples were not significantly different from either baseline or day 5 
samples. For statistical analysis, two-tailed unpaired t-test was used; *P < 0.05, **P < 0.01, and ***P < 0.001.
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in-hospital Findings
There was no in-hospital mortality and median length of 
hospitalization was 9 days (IQR). Complete blood counts were 
obtained from all patients prior to surgery and at a median of 
5 days after surgery (Table 2). Leukocyte counts (WBC count) 
did not change significantly between day 0 and day 5 (Table 2). 
NLR, the ratio between neutrophils and lymphocytes in circulat-
ing blood, has been used by some investigators as a marker of 
FigUre 5 | individual patient samples. CD16 mean fluorescence index 
(MFI) values for individual patients at day 0, day 5, and day 90. It appears 
that all patients experience an increase in CD16 MFI 5 days post-surgery; 
however, not all patients return to baseline levels of CD16 MFI at day 90.
FigUre 6 | lymphocytes and neutrophils contribution to cD16 mean fluorescence index (MFi). (a) Representative images of flow cytometry dot plots 
showing the lymphocyte population and its contribution to CD16 expression over time (nanoseconds). (B) Representative images of flow cytometry dot plots 
showing the neutrophil population and its contribution to CD16 expression over time (nanoseconds).
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inflammation (1, 5, 9). There was a significant 2.0-fold increase 
in NLR between baseline and 5 days post-surgery (p = 0.0028, 
Figure 1A). Similarly, there was a 1.7-fold increase in monocyte 
concentration in blood between baseline and 5 days after surgery 
(p = 0.0074, Figure 1B).
A standardized gating strategy was used in order to character-
ize populations of monocytes (Figure  2). The most abundant 
monocyte population was the CD14++CD16− (classical, M1) at 
88.8 ± 1.1% of all monocytes or also known as classical mono-
cytes. By contrast, CD14++CD16+ (intermediate) population 
represented 7.4 ± 0.98% of monocytes, and the CD14+CD16+ 
(non-classical, M2) subset represented 2.99 ± 0.51% of monocytes 
(Figure 2). Surgery resulted in significant changes in monocyte 
number and phenotype. A significant expansion of the interme-
diate and non-classical (M2) populations was observed at the 
expense of classical (M1) monocytes suggesting a significant shift 
toward non-classical (M2) monocytes after surgery (Figure 3). 
Upon analysis of MFI to quantify the overall CD16 expression, 
surface receptor CD16 MFI was significantly upregulated after 
surgery (day 5), but returned to baseline levels at long-term 
follow-up or 90 days after surgery (Figure 4). When we looked at 
individual patient samples (Figure 5), one can see that increases 
in CD16 MFI at day 5 are consistent despite different pre-surgery 
CD16 expression levels. Furthermore, in several patients, CD16 
MFI did not seem to return to baseline levels at day 90 and did 
not appear to correlate with adverse events given the small sample 
size. CD14 MFI showed no significant differences between pre- 
and post-surgery suggesting little change in the proportion of 
classical monocytes (Figure 4).
CD16 also known as FcγRIIIA can be expressed on mono-
cytes, macrophages, NK cells, and possibly neutrophils (PMID: 
22613847). While our data indicated that CD16 expression was 
upregulated in monocytes following surgery, we also investi-
gated its expression levels in lymphocytes and neutrophils using 
flow cytometry. Our findings suggest that CD16 expression 
was unchanged in both lymphocytes (Figure 6A) and neutro-
phils (Figure  6B), thus indicating that the elevation in CD16 
expression observed post-surgery was specific to circulating 
monocytes.
TaBle 3 | Follow-up patient grouping by development of adverse events.
Parameters no ae 
(n = 7)
With ae 
(n = 10)
p-Value
Age 65.4 ± 3.7 66.2 ± 4.2 0.89
Female gender 2/7 2/10 1.0
Diabetes 0/7 3/10 0.23
Ejection fraction 63.3 ± 3.7 57.9 ± 4.6 0.41
Atrial fibrillation 
(pre- and post-op)
3/7 3/10 0.64
BMI 30.4 ± 0.94 27.0 ± 1.5 0.11
Normal 0/7 4/10
Pre-obese 3/7 3/10
Obese I/II/III 4/7 3/10
Urgency In-hospital 5/7 9/10 0.54
Elective 2/7 1/10
Clinical frailty 4/5 1/7 6/10 0.13
Echocardiogram LV diast 4.7 ± 0.20 4.66 ± 0.15 0.80
LV syst 2.85 ± 0.05 2.74 ± 0.21 0.79
Left atrium 4.03 ± 0.44 3.94 ± 0.23 0.83
E/A 1.14 ± 0.33 1.16 ± 0.19 0.94
Cardiopulmonary 
bypass
Pump time 97.4 ± 6.1 121.8 ± 10.1 0.085
Delirium 0/7 5/10 0.044*
CHF 0/7 4/10 0.10
LOS Average 6.9 ± 0.5 18.9 ± 4.5 0.041*
PLOS > 9 days 0/7 8/10 0.0023*
Peak trop 215.9 ± 44.9 773.8 ± 179.5 0.023*
For statistical analysis, chi-squared test was used; *P < 0.05.
FigUre 7 | relationship of peak troponin and pump time with cD16 mean fluorescence index (MFi) absolute change. Graphs representing correlations 
between absolute CD16 MFI change between day 0 and day 5 and (a) peak troponin levels and (B) pump time. Both parameters were not significant with CD16 
MFI (n = 11).
FigUre 8 | relationship between cD16 mean fluorescence index 
(MFi) and neutrophil-to-lymphocyte ratio (nlr) values. Graph showing 
a positive correlation between CD16 MFI and NLR in patients’ blood 
samples. Sample size included both day 0 and day 5 findings to show the 
universal relationship between the parameters tested (n = 24).
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To better understand the mechanism by which CD16 expres-
sion is influenced by cardiac surgery using CPB, examined the 
absolute change in MFI pre- and post-surgery. CD16 expression 
correlated with two well-described variables known to influence 
inflammation after CPB: myocardial injury (troponin level post-
surgery, cTnT nanograms/milliliter) and duration of CPB (pump 
time) (16). Blood samples for cTnT analysis were obtained for 
all patients within the first 24  h post-surgery. The peak cTnT 
levels (highest cTnT value in patients with multiple samples) were 
found to be 544.1 ± 125.2 ng/mL. Correlation analyses indicated 
that there was no significant relationship between peak troponin 
and change in CD16 MFI (Figure 7A) or pump time (minutes) 
and CD16 MFI values (Figure 7B).
In the present manuscript, we evaluated both NLR and CD16 
expression as cellular markers reflecting inflammatory changes 
that occur in patients undergoing heart surgery. The correlation 
between NLR and CD16 MFI was assessed (Figure 8). By plotting 
this relationship, we were able to determine a positive correlation 
between NLR and CD16 MFI (r2 = 0.2918, p = 0.006), suggesting 
that higher NLR were associated with increased numbers of non-
classical (M2) monocytes in circulation.
Patient Outcomes and Markers of 
inflammation
All patients were followed after discharge from hospital for a 
minimum of 90 days after surgery. Follow-up was complete in 
8Gawdat et al. Circulating Leukocytes in Cardiac Surgery
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100% of patients with no in-hospital or medium term mortality. 
Adverse cardiovascular outcome (AE) was defined as any one 
of the following: prolonged length of hospitalization (LOS) 
greater than 9  days, readmission to hospital for any cardiac 
reason, persistent HF at follow-up NYHA class III or IV, and 
inability to wean diuretics for symptoms of congestion (dyspnea, 
peripheral edema). A total of 59% (10/17) of patients suffered AE 
with the majority (47%) of patients hospitalized for longer than 
9 days and 12% of patients being readmitted after discharge for 
cardiac reasons. One patient was readmitted with congestive HF 
(within 1 week of discharge) and one with an ACS (2 months 
after discharge). Patient characteristics were not significantly 
different between patients with AE (n = 10) and those without 
AE (n = 7) (Table 3). The mean length of stay was 18.9 days in AE 
patients compared to 6.9 days in those without AE (p = 0.041). 
Additionally, our unadjusted findings suggest that patients who 
develop AE have a significantly higher NLR value before surgery, 
when compared to patients who did not develop AE (p = 0.007), 
however, this failed to reach significance for CD16 MFI (p = 0.25) 
(Figure 9). Of note, patients in the AE group were more likely 
to develop delirium as a complication in hospital (0 versus 50%; 
p = 0.044) and have a significantly higher peak troponin indicat-
ing myocardial injury (215.9 + 44.9 versus 773.8 + 179.5 ng/mL; 
p = 0.023).
DiscUssiOn
It is increasingly recognized that inflammation plays a crucial 
role and may be responsible for disease progression in conditions 
like cardiovascular disease (17, 18). Similarly, inflammation has 
proven to be an important component of the normal host response 
to injury and necessary for healing. This seemingly conflicting 
role of inflammation highlights how clinically relevant efforts in 
this area remain (18). However, to date our ability to qualify or 
quantify inflammation using simple biomarkers remains poorly 
defined. In the present study, we used peripheral blood to char-
acterize circulating leukocytes namely monocytes and NLR. NLR 
was used as a marker of cellular inflammatory changes that occur 
in a group of patients undergoing heart surgery for the treatment 
of ischemic heart disease with the majority of patients having 
suffered an ACS within 21 days of surgery. Specifically, we dem-
onstrated a significant increase in NLR after surgery without a 
significant change in overall leukocyte counts. We demonstrated 
significant increases in overall neutrophil and monocyte counts 
at the expense of lymphocyte counts. Our observation is not 
unique and has been previously described (10, 19). What is novel 
about our observations is that we also correlated our findings with 
monocyte subsets based on CD16 expression. We demonstrated 
that NLR is significantly correlated with CD16 expression on 
circulating monocytes (Figure 10).
While not fully understood, monocyte-CD16 expression has 
been suggested to be a marker of maturity, sharing many features 
with tissue macrophages that have been described as non-classical 
M2 macrophages (3). It may therefore suggest that this persistence 
of non-classical M2 cells follows a heightened (NLR) preoperative 
state of inflammation that is unresolved postoperatively and thus 
contributing to AE. Our understanding of circulating monocytes 
and their phenotype has potentially important implications, as 
circulating monocytes are precursor cells to tissue macrophages. 
In the context of heart disease, increasing efforts have been made 
to better understand the balance between seemingly opposite pro-
inflammatory M1 macrophages and non-classical macrophages 
M2 (20). M2 macrophages exhibit functional characteristics that 
can exert opposing effects to classical M1 macrophages, such 
as an anti-inflammatory (IL-10) and/or pro-fibrotic cytokine 
production (TGF-β) normally associated with healing or fibrosis 
(21, 22). A proposed beneficial role for the M2 subset (non-
classical) is likely an oversimplification, given the heterogeneity 
of this population (12, 14, 20). One should note that some groups 
have suggested that larger proportions of classical CD16 mono-
cytes would be more predictive, but this was not the case in our 
study as the expression of CD14 did not change after surgery from 
baseline levels in our patient samples, indicating that classical 
(M1) monocytes were not predictive (23). The full significance 
of this observation remains to be determined; however, it could 
be that persistence of CD16 is indicative of a failure to resolve 
FigUre 9 | Differences between patients who developed adverse events post-surgery and patients who did not develop in terms of pre-op blood 
findings. (a) Graph showing a higher mean NLR value in pre-op samples of patients who developed AE when compared to pre-op samples of patients who did not 
develop AE post-surgery (p = 0.0065). (B) Graph representing CD16 mean fluorescence index (MFI) mean values at baseline in the AE and no AE patient groups (no 
significant difference was observed). For statistical analysis, two-tailed unpaired t-test was used; *P < 0.05, **P < 0.01, and ***P < 0.001.
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inflammation by M2 macrophages (providing negative feedback 
regulation) in the normal course of healing.
To date the use of CD16 expression as a biomarker to identify 
patients at risk of cardiovascular complications has yet to be widely 
applied and remains limited to case series (3, 4, 11). We argue that 
an important reason for flow cytometric analyses of blood have 
not been routinely clinically used is at least partly related to the 
fact that such assays are time consuming, labor intensive, and as 
such very expensive. To the best of our knowledge, we are the first 
to demonstrate a significant correlation between CD16 expres-
sion and clinical NLR values. Determining NLR, in contrast 
to CD16 MFI, can be obtained simply from a complete blood 
count. Complete blood counts are readily available in all patients 
undergoing surgery and are therefore convenient. Previous stud-
ies have demonstrated that NLR can be a useful biomarker for 
predicting adverse cardiovascular events after cardiac surgery or 
acute coronary events (1, 2, 5, 9). In our small study, we report 
that NLR at the time of surgery was predictive of an increased 
likelihood in developing AE after surgery supporting its use as 
a potentially useful biomarker to predict outcomes. One should 
note that in contrast to NLR, CD16 MFI was not predictive of AE 
despite showing a trend.
Despite having identified a significant correlation between 
NLR and CD16 MFI, we note that this is a small study and as 
such adjusting to potential differences between patients was not 
possible. As such, it may be that our patients were similar in terms 
of characteristics but our sample size was too small to identify 
significant differences at this stage. Previously, cardiac surgery 
patients that developed AE were sixfold more likely to be frail 
at the time of surgery (24). Clinical frailty at the time of cardiac 
surgery has been shown by our group to be a major risk factor 
for AE also (25). It is possible that NLR findings in this study not 
only reflect patient’s inflammatory state at the time of surgery, 
but could also reflect an association between inflammation and 
frailty.
An important observation from this study is the fact that 
prolonged hospitalization was the most common cause of AE 
(80%) and driven mainly by significant postoperative delirium 
(p = 0.044). Delirium is a complex clinical condition that mani-
fests clinically as an acute confused state characterized by fluctu-
ating mental status, inattention, and either disorganized thinking 
or altered level of consciousness (26). Relevant to the present 
manuscript are reports linking delirium with inflammation, but 
the mechanisms for this relationship require further study (27).
FigUre 10 | a schematic of our major findings and understanding of patient circulating leukocyte relation to cardiac surgery. Cardiac surgery with 
cardiopulmonary bypass increased the baseline levels of CD16 expression on circulating monocytes (non-classical) and neutrophil-to-lymphocyte ratio (NLR) values 
seen 5 days post-surgery with no change in overall leukocyte counts. Moreover, a positive correlation between CD16 mean fluorescence index (MFI) and NLR was 
evident. At a later follow-up time-point (day 90), a downregulation of CD16 expression was observed that seems to revert to pre-op levels of expression. Pre-op 
NLR was shown to be significantly higher in patients that later developed AE than patients who did not, therefore, putting patients with higher NLR values pre-op at 
a higher risk of developing AE. Conversely, CD16 values were not significantly different between the two groups, however, showed a trend similar to NLR.
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